<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05046158</url>
  </required_header>
  <id_info>
    <org_study_id>U-C-TPD-2021-01</org_study_id>
    <nct_id>NCT05046158</nct_id>
  </id_info>
  <brief_title>Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care</brief_title>
  <official_title>Randomized Clinical Trial to Compare Transforming Powder and Standard of Care Dressing Therapies to Heal Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ULURU Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Naval Medical Research Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Military Technology Enterprise Consortium (US)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ULURU Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase IV, randomized, prospective, multi-center, open-label, comparison of transforming&#xD;
      powder dressing to standard of care dressing for healing diabetic foot ulcers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic men and women aged 18-89 years, who have a diabetic foot ulcer present for a minimum&#xD;
      of 30 days will be considered for the study. Subjects will be randomized to either standard&#xD;
      of care wound dressings or transforming powder dressing. Half of the subjects will receive&#xD;
      standard of care dressings, and the other half will receive transforming powder dressing in a&#xD;
      1:1 randomization process at each of the study sites. Subjects will present to the study&#xD;
      center weekly for up to 12 weeks (less time if the wound heals prior to 12 weeks). The last&#xD;
      study visit occurs 12 weeks after the End of Study visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Prospective, Multi-Center, Open-Label, Comparison, Human, Interventional</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of wound closure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Compare rate of complete wound healing in diabetic foot wounds between the two study groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound healing trajectories and time to wound closure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate differences in wound healing trajectories and time to wound closure between the two study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety as indicated by adverse events (new or worsening conditions) and frequency of wound infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate subject satisfaction of wound care products based on &quot;Research subject satisfaction survey&quot; completed at the end of study (8 questions total using a 7 point Likert scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound pain</measure>
    <time_frame>12 weeks</time_frame>
    <description>Compare differences in pain between the groups based on results of a validated 10 point &quot;Visual Analogue Pain Scale&quot; completed at each visit by all subjects. More pain is indicated by higher scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life while living with a wound</measure>
    <time_frame>12 weeks</time_frame>
    <description>Compare differences in quality of life between the groups based on results of completed validated &quot;Wound Quality of Life Questionnaire for Chronic Wounds&quot; (17 questions total, answering a 5 point scale [not at all to very much], results from answers based on formula)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Acceptability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Based on clinician survey completed at end of study (8 questions total, multiple choice or 7 point Likert scale)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Transforming Powder Dressing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half of the subjects will be randomized to Transforming Powder Dressing to treat their diabetic foot ulcers. Wounds will be evaluated weekly, debrided if needed, photographed, and measured. A wound dressing will be applied using Transforming Powder Dressing and the wound will be offloaded when necessary (pressure taken off of the wound using a total contact cast or other device). Wound healing progress will be monitored and compared to other standard of care dressings used to treat diabetic foot ulcers.Surveys regarding pain and quality of life will be completed at each study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Dressing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half of the subjects will be randomized to receive standard of care wound dressings to treat their diabetic foot ulcers. Wounds will be evaluated weekly, debrided if needed, photographed, and measured. A wound dressing will be applied using standard of care wound products, and the wound will be offloaded when necessary (pressure taken off of the wound using a total contact cast or other device). Wound healing progress will be monitored and compared to transforming powder dressings used to treat diabetic foot ulcers. Surveys regarding pain and quality of life will be completed at each study visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transforming Powder Dressing</intervention_name>
    <description>Altrazeal transforming powder dressing is methacrylate-based powder dressing made from the same materials used in the production of contact lenses. Upon hydration, the powder transforms into a moist, non-occlusive barrier that covers and protects the wound from exogenous bacteria while helping manage exudate through vapor transpiration.</description>
    <arm_group_label>Transforming Powder Dressing</arm_group_label>
    <other_name>Altrazeal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care topical wound agents and dressings</intervention_name>
    <description>Standard wound dressings such as gauze or foams. Moisture regulating topical agents may also be used to prepare the wound bed.</description>
    <arm_group_label>Standard of Care Dressing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-89 years old&#xD;
&#xD;
          -  Diagnosed with diabetes Mellitus; hemoglobin A1C &lt; 12%&#xD;
&#xD;
          -  Diabetic foot ulcer present for minimum 30 days (Wagner grade 1 or 2 classification)&#xD;
&#xD;
          -  Wound drainage is minimal or moderate&#xD;
&#xD;
          -  No clinically active wound infection&#xD;
&#xD;
          -  Able and willing to provide consent&#xD;
&#xD;
          -  Has not participated in another research trial within 3 months of enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to keep weekly research appointments&#xD;
&#xD;
          -  Unable or unwilling to use offloading device if recommended&#xD;
&#xD;
          -  Wounds with large amount (high) drainage&#xD;
&#xD;
          -  Active gangrene&#xD;
&#xD;
          -  Wounds impending surgical intervention (including revascularization or plastic&#xD;
             surgery)&#xD;
&#xD;
          -  Untreated osteomyelitis&#xD;
&#xD;
          -  Soft tissue infection (can be enrolled once infection is cleared)&#xD;
&#xD;
          -  Active Charcot arthropathy&#xD;
&#xD;
          -  BMI &gt;40kg/m2&#xD;
&#xD;
          -  History of AIDS&#xD;
&#xD;
          -  History of organ transplant or impending transplant&#xD;
&#xD;
          -  End stage renal disease requiring dialysis&#xD;
&#xD;
          -  Decompensated hepatic or cardiac disease&#xD;
&#xD;
          -  Select autoimmune diseases&#xD;
&#xD;
          -  Lymphedema&#xD;
&#xD;
          -  Oral steroid use in last 3 months&#xD;
&#xD;
          -  Venous stasis disease&#xD;
&#xD;
          -  Active malignancy (cancer)&#xD;
&#xD;
          -  Unable to sign consent&#xD;
&#xD;
          -  Active alcohol or substance abuse&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Insufficient vascular flow to heal a wound&#xD;
&#xD;
          -  Hemoglobin A1C &gt;12%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Lavery, DPM, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>ULURU Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vaidehi Shah, MBA</last_name>
    <phone>646-431-9455</phone>
    <email>vshah@uluruinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan St. John, MSN, APRN-NP</last_name>
    <phone>412-303-5379</phone>
    <email>sstjohn@uluruinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Moriarty, MSN</last_name>
      <phone>202-877-3657</phone>
      <email>Theresa.M.Moriarty@medstar.net</email>
    </contact>
    <contact_backup>
      <last_name>Katelyn N Parr, RN</last_name>
      <phone>202-877-6501</phone>
      <email>Katelyn.N.Parr@medstar.net</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth Fan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Moriarty, MSN</last_name>
      <phone>202-877-3657</phone>
      <email>Theresa.M.Moriarty@medstar.net</email>
    </contact>
    <contact_backup>
      <last_name>Katelyn N Parr, RN</last_name>
      <phone>202-877-6501</phone>
      <email>Katelyn.N.Parr@medstar.net</email>
    </contact_backup>
    <investigator>
      <last_name>Michelle Magee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Good Samaritan Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Moriarty, MSN, CCRN</last_name>
      <phone>202-801-2420</phone>
      <email>Theresa.M.Moriarty@medstar.net</email>
    </contact>
    <contact_backup>
      <last_name>Mia Hamm</last_name>
      <phone>443-444-6275</phone>
      <email>Mia.A.Hamm@medstar.net</email>
    </contact_backup>
    <investigator>
      <last_name>David Z Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James J. Peters VA Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468-3904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Andriunas, RN</last_name>
      <phone>718-584-9000</phone>
      <phone_ext>6671</phone_ext>
      <email>Olga.Andriunas@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Johane Simelane, MPH</last_name>
      <phone>718-584-9000</phone>
      <phone_ext>6671</phone_ext>
      <email>Johane.Simelane@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Sheldon Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dallas Veteran's Administration Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Truong, DPM, MS</last_name>
      <phone>214-857-0039</phone>
      <email>David.Truong1@va.gov</email>
    </contact>
    <investigator>
      <last_name>David Truong, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.Altrazeal.info</url>
    <description>Altrazeal (Transforming Powder Dressing) product information</description>
  </link>
  <reference>
    <citation>Shaper NC, van Neten JJ, Apelqvist J, Bus SA, Hinchliffe RJ, Lipsky BA, IWGDF Editorial Board. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). https://doi.org/10.1002/dmrr.33266. First published 16 March 2020.</citation>
  </reference>
  <reference>
    <citation>Han G, Ceillery R. Chronic Wound Healing: A review of current management and treatments. Adv. Ther 2017; 34 (3): 599-610. Ncbi.nim.nih.gov/pmd/articles/PMC5350204/ Accessed online 11/5/2020.</citation>
  </reference>
  <reference>
    <citation>Wound Care Awareness Week Highlights of the Chronic Wound Epidemic in U.S. Businesswire.com/news/home/20160607006326/en/Wound-Care-Awareness-Week-Highlights-Chronic-Wound. Accessed 11/5/2020.</citation>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Standard of Care Wound Dressings</keyword>
  <keyword>Transforming Powder Dressing</keyword>
  <keyword>Diabetic Foot Ulcers</keyword>
  <keyword>Altrazeal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

